1/33
Looks like no tags are added yet.
Primary therapeutic purpose of β2‑agonists in asthma/COPD?
Relieve bronchoconstriction by relaxing bronchial smooth muscle.
Location of β2 receptors targeted for asthma treatment?
Bronchial smooth muscle in the lung.
Sequence of intracellular events after β2 receptor activation?
G‑protein activation → adenylyl cyclase → increased cAMP → activation of protein kinase A → reduced intracellular calcium → smooth muscle relaxation.
Functional result of increased cAMP and PKA activation in airway smooth muscle?
Reduced myosin light chain kinase activity, leading to bronchodilation.
Additional mechanism of cAMP related to inflammation?
Inhibits release of mediators from mast cells.
Define SABAs and their clinical role.
Short‑acting β2‑agonists used for immediate symptom relief and rescue therapy.
Examples of SABAs.
- Albuterol
- salbutamol
- terbutaline
- epinephrine
- isoproterenol.
Typical duration of action for SABAs.
Less than two hours.
Reason SABAs used for emergencies.
Fast onset and quick relaxation of airway smooth muscle.
Define LABAs and their clinical role.
Long‑acting β2‑agonists used for maintenance and prevention of chronic symptoms.
Examples of LABAs.
- Salmeterol
- olodaterol
- formoterol
- vilanterol
- indacaterol
Reason LABAs are long‑acting.
Long pulmonary residence time.
Why formoterol is used with budesonide in mild asthma?
Faster onset of action allows symptom relief with continued maintenance.
Two major inhalation delivery devices for β2‑agonists.
Metered‑dose inhalers and dry powder inhalers.
Characteristic of dry powder inhalers.
Breath‑activated; effectiveness depends on inhalation flow rate.
Population where DPI may be less effective.
Patients with severe airflow limitation.
Purpose of a spacer with MDIs.
Improves lung deposition and reduces drug in mouth and throat.
Desired receptor selectivity profile for β2‑agonists.
High β2 affinity and low β1 affinity.
Reason high β1 affinity is undesirable.
Increases heart rate and cardiovascular side effects.
Typical clinical use of SABAs.
Rescue medication for acute bronchoconstriction.
Typical clinical use of LABAs.
Maintenance therapy for moderate to severe persistent asthma or COPD.
Most common adverse effect of β2‑agonists.
Tremor from β2 stimulation in skeletal muscle.
Cardiac side effect of β2‑agonists and reason.
Tachycardia due to stimulation of β1 and β2 receptors in the heart.
Metabolic side effects linked to β2‑agonists.
Hyperglycemia and reduced plasma potassium.
Other possible side effects.
Headache, bronchospasm, dizziness, pharyngitis, pain.
Original concern leading to FDA black box for LABAs.
Increased asthma‑related deaths when LABAs used alone.
Reason FDA removed black box for combination LABA + corticosteroid products.
Studies showed no increased risk when LABAs only used with corticosteroids.
Does black box warning still apply to LABA monotherapy?
Yes.
Metabolic pathway important for β2‑agonist interactions.
CYP3A4.
Potent CYP3A4 inhibitors that increase β2‑agonist systemic levels.
Ketoconazole and ritonavir.
Drugs requiring extreme caution because they potentiate vascular effects of salmeterol.
MAO inhibitors and tricyclic antidepressants.
Effect of combining β‑blockers with β2‑agonists.
Blocks bronchodilation and may cause severe bronchospasm.
Interaction with digoxin.
May decrease digoxin levels.
Interaction with diuretics.
May worsen hypokalemia.